Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months […]
South San Francisco-based Genentech revealed the impressive results of its Phase III Krascendo 1 study, which showcased the superior efficacy of divarasib, a next-generation KRAS G12C inhibitor, over current standard-of-care KRAS G12C inhibitors for patients with previously treated non-small cell lung cancer (NSCLC) that has the KRAS G12C mutation.
Participants who received divarasib monotherapy demonstrated a significantly lower risk of death by 44% compared to those treated with sotorasib or adagrasib, with overall survival (OS) increasing to approximately 18 months, versus 12 months for the control group. The data were presented as a late-breaking abstract at the 2026 European Society for Medical Oncology (ESMO) Congress and published simultaneously in The New England Journal of Medicine.
Divarasib showed no new safety findings, with the most common treatment-related adverse events (TRAEs) being mainly low-grade and manageable.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
